-+ 0.00%
-+ 0.00%
-+ 0.00%

C4 Therapeutics doses first patient in Phase 1b cemsidomide-elranatamab trial for relapsed/refractory multiple myeloma; enrollment grows to 54 patients

Reuters·03/25/2026 11:01:28

Please log in to view news